Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT03713957
Registration number
NCT03713957
Ethics application status
Date submitted
18/10/2018
Date registered
22/10/2018
Date last updated
9/05/2022
Titles & IDs
Public title
A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment
Query!
Scientific title
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment
Query!
Secondary ID [1]
0
0
Alkahest study 6021-201
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Parkinson Disease
0
0
Query!
Condition category
Condition code
Neurological
0
0
0
0
Query!
Parkinson's disease
Query!
Mental Health
0
0
0
0
Query!
Other mental health disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - GRF6021
Other interventions - Placebo
Experimental: GRF6021 - Subjects will receive GRF6021 for 5 consecutive days at Week 1 and Week 13.
Placebo comparator: Placebo - Subjects will receive Placebo for 5 consecutive days at Week 1 and Week 13.
Treatment: Drugs: GRF6021
GRF6021 for IV infusion
Other interventions: Placebo
Placebo for IV infusion
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Incidence of Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Query!
Assessment method [1]
0
0
Treatment-emergent adverse events identified by MedDRA preferred term and grouped by MedDRA System Organ Class
Query!
Timepoint [1]
0
0
Approximately 24 Months
Query!
Secondary outcome [1]
0
0
The Montreal Cognitive Assessment (MoCA) Score.
Query!
Assessment method [1]
0
0
Change from baseline in the The Montreal Cognitive Assessment (MoCA). The MoCA is a 30-point test, which assess the attention and concentration, executive functions, memory, visuospatial abilities, language abilities, conceptual thinking, calculations, and orientation. Higher scores indicate better cognitive function; the total possible score is 30 and a score of 26 or more is considered normal. A positive value of change means an improvement, and a negative value of change means deterioration. Score range \[0 (min) - 30 (Max)\].
Query!
Timepoint [1]
0
0
Change from Baseline to Week 16
Query!
Secondary outcome [2]
0
0
Continuity of Attention, Reaction Time Variability, Working Memory, and Episodic Memory on the Cognitive Drug Research Computerized Cognition Battery (CDR-CCB) as Assessed by Change From Baseline in CDR-CCB.
Query!
Assessment method [2]
0
0
The CDR-CCB is an automated cognitive function assessment system. The secondary efficacy outcomes involved the following composite scores:
* Continuity of Attention: Min: - 20 # ; 35 #
* Reaction Time Variability: Min: 0 #; Max: 900 #
* Quality of Working Memory: Min : 0 # ; Max: 2 #
* Quality of Episodic Memory: Min: -400 #; Max: 400 #
Note: # denotes "no specific unit"
Lower scores reflect poorer ability for Continuity of Attention, Quality of Working Memory, and Quality of Episodic Memory; thus, a negative change from baseline reflects impairment compared to baseline. Whereas, for Reaction Time Variability, higher scores reflect poorer ability, and a positive change from baseline reflects impairment compared to baseline.
Query!
Timepoint [2]
0
0
Change from Baseline to Week 20
Query!
Secondary outcome [3]
0
0
The Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency.
Query!
Assessment method [3]
0
0
Change from baseline in the Delis-Kaplan Executive Function System (D-KEFS). The D-KEFS Verbal Fluency test is used for assessment of executive function and has three conditions: Letter Fluency, Category Fluency, and Category Switching. Higher scores indicate more correct responses. A positive value of change means an improvement and a negative value of change means deterioration. The minimum score is 0 and there is no concrete maximum score.
Query!
Timepoint [3]
0
0
Change from Baseline to Week 20
Query!
Secondary outcome [4]
0
0
The Movement Disorder Society's Unified Parkinson's Disease Rating Scale (MDS-UPDRS) 1, 2, 3, and Total Score.
Query!
Assessment method [4]
0
0
Change from baseline in the Movement Disorder Society's Unified Parkinson's Disease Rating Scale (MDS-UPDRS). The MDS-UPDRS contains 4 subscales: Part 1, Mentation, Behavior, and Mood; Part 2, Activities of Daily Living; Part 3, Motor; Part 4, Complications nonmotor experiences of daily living (13 items), motor experiences of daily living (13 items), motor examination (18 items), and motor complications (six items). The rating for each item is from 0 (normal) to 4 (severe). The total score for each Part is obtained from the sum of the corresponding item scores. For this study, Parts 1-3 will be completed. Part 1 score ranges from 0 to 52. Part 2 score ranges from 0 to 52. Part 3 score ranges from 0 to 132. Total score possible is 0 to 236.
Query!
Timepoint [4]
0
0
Change from Baseline to Week 16
Query!
Secondary outcome [5]
0
0
The Schwab and England Activities of Daily Living (SE-ADL) Scale.
Query!
Assessment method [5]
0
0
Change from baseline in the Schwab and England Activities of Daily Living (SE-ADL). The SE-ADL evaluates patients' perceptions of global functional capacity and dependence. Scoring is expressed in terms of percentage, in 10 steps from 100 to 0 (100%, normal status; 0%, bedridden with vegetative dysfunction), so that the lower the score, the worse the functional status. The range is 0% to 100%.
Query!
Timepoint [5]
0
0
Change from Baseline to Week 24
Query!
Secondary outcome [6]
0
0
The Clinical Impression of Severity Index - PD (CISI-PD).
Query!
Assessment method [6]
0
0
Change from baseline in The Clinical Impression of Severity Index PD (CISI-PD). The CISI-PD is a severity index formed by four items (motor signs, disability, motor complications, and cognitive status), rated 0 (not at all) to 6 (very severe or completely disabled); the possible scores range from 0 to 24. A total score is calculated by summing the item scores. Higher scores indicate worse severity. A negative value of change means an improvement and a positive value of change means deterioration.
Query!
Timepoint [6]
0
0
Change from Baseline to Week 24
Query!
Secondary outcome [7]
0
0
The Parkinson's Disease Quality of Life Questionnaire-39 (PDQ-39).
Query!
Assessment method [7]
0
0
Change from baseline in the Parkinson's Disease Quality of Life Questionnaire-39 (PDQ-39). The PDQ-39 is a self-administered questionnaire of 39 questions relating to 8 key areas of health and daily activities, including both motor and non-motor symptoms. It is scored on a scale of 0 -100 with lower scores indicating better health and high scores indicating more severe symptoms.
Query!
Timepoint [7]
0
0
Change from Baseline to Week 20
Query!
Secondary outcome [8]
0
0
The Geriatric Depression Scale-15 (GDS-15).
Query!
Assessment method [8]
0
0
Change from baseline in the Geriatric Depression Scale (GDS-15). The GDS-15 is a 15-item yes/no questionnaire of depression in older adults. Each depressive answer is 1 point. The final score is the tally of the number of depressive answers with the following scores indicating depression: 0-4 No depression; 5-10 Suggestive of a mild depression; 11 + Suggestive of severe depression. The possible scores range from 0 - 15.
Query!
Timepoint [8]
0
0
Change from Baseline to Week 20
Query!
Secondary outcome [9]
0
0
The Digital Clock Drawing Test (dCDT).
Query!
Assessment method [9]
0
0
Change from baseline in the digital clock drawing test (dCDT). The pen-like dCDT device will be used to gather the x-y coordinates that describe the movement of the stylus as it changes its position during the assessment. It also assesses when the stylus or writing device is not exerting pressure on the writing surface. The dCDT score is a number from 0 and 100 that represents a person's overall cognitive function as assessed by DCT clock. The total possible score is 100. A negative value of change means a deterioration and a positive value of change means an improvement.
Query!
Timepoint [9]
0
0
Change from Baseline to Week 20
Query!
Secondary outcome [10]
0
0
Power of Attention, Cognitive Reaction Time, and Speed of Memory on the Cognitive Drug Research Computerized Cognition Battery (CDR-CCB) as Assessed by Change From Baseline in CDR-CCB.
Query!
Assessment method [10]
0
0
The CDR-CCB is an automated cognitive function assessment system. The secondary efficacy outcomes involved the following composite scores:
* Power of Attention: Min: 350 ms ; Max: 60000 ms
* Cognitive Reaction Time: Min: - 30000 ms; Max : 30000 ms
* Speed of Memory: Min 800 ms; Max: 120000 ms
Higher scores reflect poorer ability, and a positive change from baseline reflects impairment compared to baseline.
Query!
Timepoint [10]
0
0
Change from Baseline to Week 20
Query!
Eligibility
Key inclusion criteria
* Diagnosis of Parkinson's Disease (PD), with at least 1 year of PD symptoms.
* Diagnosis of PD with mild cognitive impairment (PD-MCI) or probable or possible Parkinson's disease dementia according to Movement Disorder Society's Clinical Diagnostic criteria.
* Score on the Montreal Cognitive Assessment (MoCA) of 13-25.
* Modified Hoehn and Yahr Stages 1-4.
* Modified Hachinski Ischemic Scale (MHIS) score of 4 or less.
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
85
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* History of blood coagulation disorders or hypercoagulability.
* Current use of anticoagulant therapy. Use of antiplatelet drugs (e.g., aspirin or clopidogrel) is acceptable.
* Prior hypersensitivity reaction to any human blood product or any IV infusion.
* Treatment with any human blood product, including transfusions and IV immunoglobulin, during the 6 months prior to screening.
* History of immunoglobulin A or haptoglobin deficiency; stroke, anaphylaxis, or thromboembolic complications of IV immunoglobulins.
* Heart disease, as evidenced by myocardial infarction, unstable, new onset or severe angina, or congestive heart failure in the 6 months prior to dosing
* Hemoglobin < 10 g/dL in women and < 11 g/dL in men.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
12/11/2018
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
20/07/2020
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
79
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Alfred Hospital - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
3004 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arkansas
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Michigan
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Missouri
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
North Carolina
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Ohio
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Oregon
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Texas
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Washington
Query!
Country [12]
0
0
France
Query!
State/province [12]
0
0
Bron
Query!
Country [13]
0
0
France
Query!
State/province [13]
0
0
Creteil
Query!
Country [14]
0
0
France
Query!
State/province [14]
0
0
Grenoble
Query!
Country [15]
0
0
France
Query!
State/province [15]
0
0
Lille
Query!
Country [16]
0
0
France
Query!
State/province [16]
0
0
Marseille
Query!
Country [17]
0
0
France
Query!
State/province [17]
0
0
Nimes
Query!
Country [18]
0
0
France
Query!
State/province [18]
0
0
Poitiers
Query!
Country [19]
0
0
France
Query!
State/province [19]
0
0
Rouen
Query!
Country [20]
0
0
France
Query!
State/province [20]
0
0
Toulouse
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Alkahest, Inc.
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
Michael J. Fox Foundation for Parkinson's Research
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study will evaluate the safety, tolerability, and potential effects on cognition of GRF6021, a plasma-derived product, administered as an intravenous (IV) infusion, to subjects with Parkinson's disease and cognitive impairment.
Query!
Trial website
https://clinicaltrials.gov/study/NCT03713957
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Alkahest Medical Monitor
Query!
Address
0
0
Alkahest, Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/57/NCT03713957/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/57/NCT03713957/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT03713957
Download to PDF